文献速递乳腺US

潜在治疗靶点的浮现:基于超声的影像组学预测人表皮生长因子受体2低表达乳腺癌

The Emergence of the Potential Therapeutic Targets: Ultrasound-Based Radiomics in the Prediction of Human Epidermal Growth Factor Receptor 2-Low Breast Cancer.
PubMed 文献 · Acad Radiol · 2024-02-02

基于常规超声的影像组学评分被证明可有效预测乳腺癌HER2低表达。

要点

  • 基于常规超声的影像组学评分可用于区分HER2零表达与HER2低表达及阳性乳腺癌。
  • 该评分在训练集、内部验证集和外部验证集AUC分别为0.81、0.84和0.82。
  • 亚组分析中区分HER2零表达与HER2 1+、2+及低表达肿瘤的AUC范围为0.79-0.87。

核心结论

  • 基于常规超声的影像组学评分被证明可有效预测乳腺癌HER2低表达。

研究设计与样本

  • 多中心研究,机构1的383例为训练集,机构2的233例为验证集,机构3的149例为外部验证集,纳入2021年1月至2023年6月接受超声扫描且病理确诊乳腺癌的患者。

诊断标准与关键数值

  • 影像组学评分区分HER2零表达与HER2低表达及阳性病例的AUC:训练集0.81(95%CI 0.76-0.84),验证集0.84(95%CI 0.78-0.88),外部验证集0.82(95%CI 0.73-0.90)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To evaluate whether ultrasound-based radiomics features can effectively predict HER2-low expression in patients with breast cancer (BC).

MATERIAL AND METHODS: Between January 2021 and June 2023, patients who received US scans with pathologically confirmed BC in this multicenter study were included. In total, 383 patients from institution 1 were comprised of training set, 233 patients from institution 2 were comprised of validation set and 149 patients from institution 3 were comprised of external validation set. Radiomics features were derived from conventional ultrasound (US) images. The minimum redundancy and maximum relevancy and the least absolute shrinkage and selector operation algorithm were used to generate an US-based radiomics score (RS). Multivariable logistic regression analysis was used to select variables associated with HER2 expressions. The diagnostic performance of the RS was evaluated through the area under the receiver operating characteristic curve (AUC).

RESULTS: In the training set, the RS yield an AUC of 0.81 (95%CI: 0.76-0.84) for differentiation HER2-zero from HER2-low and -positive cases, and performed well in validation set (AUC 0.84, 95%CI: 0.78-0.88) and external validation set (AUC 0.82, 95%CI: 0.73-0.90). In the subgroups analysis, the RS showed good performance in distinguishing HER2-zero from HER2 1 + , HER2 2 + and HER2-low tumors (AUC range, 0.79-0.87).

CONCLUSION: The RS based on conventional US is proven effective for predicting HER2-low expression in BC.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Du Y, Li F, Zhang M, et al. The Emergence of the Potential Therapeutic Targets: Ultrasound-Based Radiomics in the Prediction of Human Epidermal Growth Factor Receptor 2-Low Breast Cancer. Acad Radiol. 2024. PMID: 38309977. doi:10.1016/j.acra.2024.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。